Generic Medicine Info
Indications and Dosage
Secondary bacterial infection of acute bronchitis
Adult: 200-400 mg 12 hrly for 7 days.

Skin and soft tissue infections
Adult: 200 mg 12 hrly for 7 days.
Child: 6 mth-12 yr: 7.5 mg/kg 12 hrly for 7 days.

Uncomplicated urinary tract infections
Adult: 200 mg daily for 7 days.

Acute bacterial exacerbation of chronic bronchitis
Adult: 400 mg 12 hrly for 7 days.

Acute otitis media
Child: 6 mth-12 yr as oral suspension: 15 mg/kg 12 hrly for 10 days.

Adult: 400 mg 12 hrly for 10 days.
Child: 6 mth-12 yr: 15 mg/kg 12 hrly for 10 days.

Pneumonia, Pyelonephritis
Adult: 400 mg 12 hrly for 14 days.

Pharyngitis, Tonsillitis
Adult: 200 mg 12 hrly for 10 days.
Child: 6 mth-12 yr: 7.5 mg/kg 12 hrly for 10 days.
Renal Impairment
Patients with CrCl of 10-49 mL/min: Half the usual dose at the usual dosage interval or full dose at twice the usual interval; <10 mL/min: Usual dose every 3-5 days. Patients on haemodialysis should receive another dose following dialysis.
Should be taken on an empty stomach. Take 1 hr before or at least 2 hr after meals.
Hypersensitivity to β-lactams.
Special Precautions
Impaired renal function, history of colitis.
Adverse Reactions
Diarrhoea, nausea, vomiting, abdominal pain; headache; skin rashes; abnormalities in haematological parameters; elevations in hepatic enzymes, hepatic dysfunction.
Drug Interactions
Plasma concentration is increased by probenecid.
Description: Loracarbef is a carbacephem antibiotic. It is bactericidal through binding to essential target proteins of the bacterial cell wall, leading to inhibition of cell-wall synthesis, thus preventing cell division.
Absorption: Well absorbed from GI tract. Peak plasma levels after 1.2 hr (capsule) or 40-60 min (liquid). Absorption delayed significantly by food.
Distribution: 25% bound to plasma proteins.
Excretion: Excreted in the urine as unchanged drug.
MIMS Class
Other Beta-Lactams
Disclaimer: This information is independently developed by MIMS based on Loracarbef from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in